



Impact of sodium-hydrogen exchange inhibition by
cariporide on death or myocardial infarction in high-risk
CABG surgery patients: Results of the CABG surgery cohort
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Objectives: To evaluate the effects of cariporide on all-cause mortality or myocar-
dial infarction at 36 days in patients at risk of myocardial necrosis after coronary
artery bypass graft surgery.
Methods: In the coronary artery bypass graft cohort of the GUARD During Ischemia
Against Necrosis trial, patients 18 years who required urgent coronary artery
bypass graft, repeat coronary artery bypass graft, or had a history of unstable angina
and 2 risk factors (age 65 years, female gender, diabetes mellitus, ejection
fraction 35%, or left main or 3-vessel disease) were randomized to placebo
(n  743) or cariporide 20 mg (n  736), 80 mg (n  705), or 120 mg (n  734).
A 1-hour intravenous infusion was initiated shortly before surgery and administered
every 8 hours for 2 to 7 days. Patients were followed up for 6 months. A nonparametric
covariance analysis was used to calculate the primary efficacy endpoint.
Results: Baseline characteristics were similar between treatment groups. The cari-
poride 20- and 80-mg groups had event rates similar to placebo. The endpoint of
all-cause mortality or myocardial infarction at day 36 was significant with cariporide
120 mg versus placebo (event rate 12.2% vs 16.2%; P  .027). The risk reduction
was evident on postoperative day 1 (3.3% vs 6.5%; P  .005) and was maintained
at 6 months (event rate 15.0% vs 18.6%; P  .033). Cariporide was well tolerated,
and most adverse events were mild and transient in this high-risk population.
Conclusions: Clinical benefit with cariporide 120 mg was observed early after
treatment initiation and continued for 6 months postsurgery, suggesting that sodium-
hydrogen exchange inhibition with cariporide is cardioprotective in patients under-
going high-risk coronary artery bypass graft surgery.
Refinements in coronary artery bypass graft (CABG) surgery sincethe first bypass procedure was performed in 1967 have led to anexpected 30-day mortality of 1% in low-risk patients.1,2 Predic-tive factors of increased mortality after CABG include the urgencyof the operation, previous heart surgery, age 65 years, left ven-tricular dysfunction, female gender, and left main or 3-vessel
disease.3 The prevalence of high-risk CABG patients is increasing due to an aging
population, improving survival of coronary heart disease patients, and expanding
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use of percutaneous transluminal coronary angioplasty
(PTCA), which may prolong the time before a patient ulti-
mately presents for CABG.1 Thus, a need exists for new
treatment options to improve mortality and morbidity out-
comes after CABG in high-risk patients.
Sodium-hydrogen exchanger (NHE) activation is associ-
ated with cell injury and necrosis in myocardial ischemia
and reperfusion states.4 NHE-1, 1 of 6 identified NHE
isoforms, is the predominant isoform in cardiomyocytes.5,6
During myocardial hypoxia and ischemia, anaerobic metab-
olism leads to intracellular acidosis. NHE-1 is activated to
regulate the intracellular pH by extruding hydrogen in ex-
change for sodium.7-9 The increase in intracellular sodium
in turn activates Na-Ca2 exchange. The resultant increase
in intracellular Ca2 directly mediates cell death by pro-
tease activation, cell contracture, and membrane rup-
ture.4,5,7,10,11 Cariporide, a novel NHE-1 inhibitor, reduces
Na influx and, in turn, Ca2 overload during ischemia or
reperfusion.10,11 Preclinical studies have demonstrated a
cardioprotective effect in animal models.12-17 Recently, the
first large-scale study, the GUARD During Ischemia
Against Necrosis (GUARDIAN) trial, evaluated the effect
of cariporide on the composite endpoint of all-cause mor-
tality and myocardial infarction (MI) at day 36 in 11,590
patients in different clinical settings at risk of myocardial
necrosis. Although in the overall analysis no significant
reduction was achieved by any of the 3 cariporide groups,18
a nominally significant reduction in the primary endpoint
incidence was observed in the entry category of patients
undergoing CABG who were treated with cariporide
120 mg, as evidenced by a 25% relative risk reduction
(RRR) (P  .027). This observation prompted more de-
tailed analyses of the findings in the CABG cohort of the
GUARDIAN study, which are the subject of this publica-
tion.
Methods
Patients presenting with unstable angina (UA) or non–Q-wave MI
or undergoing high-risk coronary revascularization (PTCA or
CABG) were enrolled from May 1997 to April 1999 at 382 study
sites in 23 countries in this randomized, placebo-controlled, dou-
ble-blind, parallel group trial.11 The clinical study protocol and
informed consent documents were reviewed and approved by an
institutional review board for each study center. Signed informed
consent was obtained from each study participant before enroll-
ment. The study was conducted in accordance with good clinical
practice as indicated in the Declaration of Helsinki.
The study design of the GUARDIAN trial has been pub-
lished.11,18 The CABG cohort included patients 18 years of age
who required urgent CABG, repeat CABG, or had angina at rest or
with minimal exercise within the previous 4 weeks and 2 of the
following risk criteria: age 65 years, female gender, diabetes
mellitus, ejection fraction 35%, or left main or 3-vessel disease.
Exclusion criteria included persistent ST elevation or new Q-wave
MI, secondary causes of UA, cardiogenic shock or pulmonary
edema refractory to medical treatment, permanent ventricular pac-
ing, automated implanted cardiac defibrillator, or left bundle
branch block. Other exclusion criteria included elevations in liver
function tests 3 times the upper limit of normal (ULN), serum
bilirubin 1.75 mg/dL (30 mol/L), serum creatinine
2 mg/dL (177 mol/L), clinically severe hepatic or renal
impairment, and women who were breastfeeding or pregnant.
Patients who had previous exposure to cariporide, had a history of
hypersensitivity to amiloride, or who had participated in an inves-
tigational study within 30 days were also excluded.
On enrollment, patients were randomized to 4 parallel treat-
ment groups. A 1-hour intravenous infusion of cariporide 20, 80,
or 120 mg or placebo was initiated 15 minutes to 2 hours before
surgery and administered every 8 hours for2 days to a maximum
of 7 days. The dose of cariporide was adjusted for patients with a
serum creatinine of 1.5 to 2.0 mg/dL (133-177 mol/L) at baseline
or a creatinine of 1.5 to 3.0 mg/dL (133-265 mol/L) during
treatment. Cariporide was discontinued after the investigator de-
termined that the patient was clinically stable and symptom-free
for 12 to 24 hours (or 24 hours prior to discharge).
The primary endpoint was the combined incidence of all-cause
mortality or MI at day 36 in patients undergoing CABG. Second-
ary endpoints included all-cause mortality or MI at 10 days, events
related to left ventricular dysfunction (LVD) [ie, composite end-
point of cardiac-related mortality, MI, cardiogenic shock, conges-
tive heart failure (CHF), and life-threatening arrhythmia] at day 36
and at 6 months, refractory ischemia at day 36, and peak creatine
kinase with muscle and brain subunits (CK-MB) levels measured
to assess the extent of infarction. The safety and tolerability of
study medications were assessed throughout the trial.
Enrollment evaluations included complete physical examina-
tion, 12-lead electrocardiogram (ECG), standard laboratory assess-
ment, and total creatine kinase (CK) and CK-MB isoenzymes.
Additionally, an ECG was performed 24 to 72 hours after surgery,
and serial serum CK-MB values were obtained 8, 12, 18, and 24
hours after surgery. The diagnosis of Q-wave MI was determined
by ECG criteria of a 2-step Q-wave change as defined by the
Minnesota code.19 In the absence of a new Q-wave, a CK-MB
elevation 100 U/L (or 100 ng/mL, if a CK-MB mass assay was
used) within 24 hours of CABG was considered indicative of
non–Q-wave MI. If CK-MB values continued to elevate after 24
hours without a trough value, the highest value was chosen to
represent peak CK-MB elevation. Furthermore, the protocol spec-
ified that when a patient reported chest pain 20 minutes during
the postoperative phase, an additional ECG should be obtained and
serial CK-MBs be repeated at 4, 8, 12, and 24 hours. In this case,
MI was diagnosed in patients who had a re-elevation of CK-MB
occurring after a prior nadir that exceeded 2  ULN and exhibited
a typical rise and fall. After surgery, non–Q-wave MI was diag-
nosed as evidenced by a 2-fold increase in CK-MB in the
absence of a percutaneous intervention, or 3-fold increase after
percutaneous intervention. At discharge or on day 10 for patients
who were still hospitalized, physical examination, ECG, and lab
assessments were repeated. Follow-up evaluations were performed
at day 36 and 6 months and included blood pressure, pulse, ECG,
concomitant medications, and review of endpoints. In addition to
MI reported by the investigators, CK-MB values and ECG from all
patients were screened for presence of previously unreported “da-
Boyce et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 2 421
CS
P
tabase-identified MI” by a central ECG Core Laboratory (B. Chait-
man, MD, St. Louis, Mo), which was blinded to treatment assign-
ments throughout the study. All primary and secondary endpoints
were further validated by an independent, blinded “endpoint val-
idation committee.”
Efficacy analyses were performed on all randomized patients
(ie, intent to treat). A nonparametric covariance adjustment anal-
ysis20 was used to calculate probability values and 98% confidence
limits for the primary endpoint. Predefined covariates included
age, sex, CHF diabetes, index MI, previous MI, ST-segment de-
pression, and cerebrovascular or peripheral vascular disease. To
test for homogeneity of the covariates, the Wilcoxon rank sum test
was used for continuous variables, and Fisher exact test was used
for categoric data. The square root of the unadjusted 2 statistics
was calculated, and Kaplan-Meier curves were used to present
time to first primary endpoint event. The same methodology, when
appropriate, was used to analyze the secondary efficacy endpoints.
An extended Mantel-Haenszel statistic examined the peak CK-MB
scores. Safety analyses were performed on the treated population
using Fisher exact tests.
Results
Baseline Demographics
Of the 11,590 patients enrolled in the GUARDIAN trial,
2918 (25.2%) were in the CABG entry cohort and were
randomized to treatment with cariporide 20, 80, or 120 mg,
or placebo (Table 1). Baseline characteristics were similar
between treatment groups. The median time from the first
cariporide infusion to anesthesia induction was 1 hour.
Mean treatment duration was approximately 3 days, during
which a median number of 8 infusions were administered.
The number of patients requiring a dose reduction increased
as the cariporide dosage increased, primarily because of
elevations in serum creatinine.
Efficacy
The primary endpoint of all-cause mortality or MI at day 36
was significantly reduced in the cariporide 120-mg treat-
ment group compared with placebo (event rate 12.2% vs
16.2%; P  .027) (Table 2, Figure 1). A significant reduc-
tion in event rates was apparent within 24 hours after
initiating cariporide 120 mg and continued throughout the 6
months of follow-up (Table 2). The primary cause of death
was cardiovascular, and no significant difference was ob-
served between treatment groups for either cardiovascular
or total death (Table 3). Thus, the reduction in risk was
attributed to fewer nonfatal Q-wave and non–Q-wave MIs.











Male 521 (70.1) 517 (70.2) 483 (68.5) 507 (69.1)
Female 222 (29.9) 219 (29.8) 222 (31.5) 227 (30.9)
Age [n (%)]
55 y 97 (13.1) 75 (10.2) 78 (11.1) 83 (11.3)
55-64 y 160 (21.5) 153 (20.8) 134 (19.0) 168 (22.9)
65-74 y 337 (45.4) 366 (49.7) 324 (46.0) 333 (45.4)
75 y 148 (19.9) 142 (19.3) 169 (24.0) 150 (20.4)
Race [n (%)]
Caucasian 699 (94.1) 696 (94.6) 658 (93.3) 697 (95.0)
African American 28 (3.8) 31 (4.2) 29 (4.1) 24 (3.3)
Asian 11 (1.5) 4 (0.5) 9 (1.3) 5 (0.7)
Multiracial 5 (0.7) 5 (0.7) 9 (1.3) 7 (1.0)
Smoker or previous smoker [n (%)] 483 (65) 496 (67.4) 456 (64.7) 474 (64.5)
BMI (mean  SD) 28.1 4.7 28.2 5.7 27.9 4.7 28.1 4.6
Obese (ie, 28 kg/m2) [n (%)] 343 (46.2) 332 (45.2) 319 (45.4) 333 (45.4)
Cardiac history (%)
History of MI 51.5 52.2 52.7 48.5
MI at study entry 5.5 4.9 6.7 4.9
CHF 9.3 10.9 9.4 9.7
Diabetes 36.9 36.9 42.3 41.7
CVD 7.8 8.7 9.1 12.9
PVD 17.4 19.3 16.9 18.1
UA 59.3 61.4 58.8 59.0
Previous cardiac interventions (n)
Previous PTCA 18.6 20.0 18.5 18.3
Previous CABG 16.3 17.1 17.0 16.6
BMI, Body mass index; CABG, coronary artery bypass graft; CHF, congestive heart failure; CV, cardiovascular; CVD, cerebrovascular disease; HTN,
hypertension; MI, myocardial infarction; NA, not applicable; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease; SD,
standard deviation; UA, unstable angina; y, year.
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There was a 32% RRR in nonfatal MIs with cariporide
120 mg compared with placebo. The cariporide 20- and
80-mg groups had event rates similar to placebo.
Infarction size was estimated according to peak CK-MB
levels. The reduction in the incidence of MI in the cariporide
120-mg group was associated with fewer patients having in-
creased peak CK-MB values compared with placebo (Table 4).
To account for variations between laboratories, the ratio of the
peak CK-MB value to the ULN was calculated; patients re-
ceiving cariporide 120 mg had a significant reduction in this
ratio compared with patients receiving placebo (6.47 vs 8.00;
P  .021). No significant reduction in peak CK-MB values
occurred with the 20- and 80-mg treatment groups.
LVD-associated events were reduced at 6 months in the
120-mg treatment group compared with placebo (9.4% vs
13.5%, respectively) primarily because of the lower inci-
dence of MI. Other secondary endpoints, including cardio-
vascular death, cardiogenic shock, overt CHF, and life-
threatening arrhythmias, were not different between cariporide
treatment groups or placebo at 36 days. Additionally, the
frequency of refractory ischemia at 36 days and rehospitaliza-
tion were comparable between treatment groups. However, the
rehospitalization rate due to endpoint events was slightly lower
with cariporide 120 mg compared with cariporide 20 and 80
mg and placebo (7.8% vs 11.5%, 13.2%, and 14.7%, respec-
tively).
Subgroup analyses were performed on the endpoints of
all-cause mortality or MI at 36 days to clarify the risk
reduction in patients treated with cariporide 120 mg
(Table 5). The reduction in event rates was maintained with
cariporide 120 mg compared with placebo in patients with
UA and 2 or more risk factors (11.6% vs 15.2%), or 3 or
more risk factors (14.1% vs 16.8%) and in patients under-
going repeat CABG (18.4% vs 27.2%). The only exception
was for the small group of patients requiring urgent CABG
(10% of the total cohort), in whom the event rate was
14.2% with cariporide vs 10.8% with placebo. The duration
of CABG surgery was also assessed regarding its potential
influence on treatment effects. The percentage of event rates
for cariporide 120 mg was lower than for the other treat-
ments during short (4.2 hours), medium (4.2-4.9 hours),
and long (4.9 hours) procedures. The difference in event
rates was most pronounced in the one third of patients with
the longest duration of surgery (4.9 hours), and with the
longest aortic crossclamp time 105 minutes, where the
event rates were 18.1% and 19.8% with cariporide 120 mg,
respectively, and 25.3% with placebo. A reduction in the
event rate was observed irrespective of whether the patients
received blood cardioplegia (14.0% vs 18.5%) or crystalloid
cardioplegia (9.0% vs 14.1%). (Note: Since patients were
not randomly assigned to receive either blood or crystalloid
cardioplegia, overall event rates for the different cardiople-
gia strategies are not comparable). Event rates were some-
what higher for patients treated in the United States/Canada
(12.8% with cariporide 120 mg vs 16.1% with placebo)
compared with Europe/rest of world (11.0% vs 16.2%) but
again similar risk reductions were observed between treat-
ment groups in both geographic regions.











Event rate (%) 6.46 7.20 6.24 3.27
RRR (%) – 8.41 0.47 48.92
P value – .676 .980 .005
Day 5
Event rate (%) 14.16 14.41 14.49 9.56
RRR (%) – 0.23 4.33 32.34
P value – .985 .740 .007
Day 10
Event rate (%) 14.71 15.66 15.78 10.53
RRR (%) – 4.99 9.11 28.47
P value – .692 .480 .016
Day 36
Event rate (%) 16.22 17.30 17.37 12.23
RRR (%) – 5.00 8.70 24.69




18.57 19.43 19.57 14.99
P value .829 .658 .033
MI, Myocardial infarction; RRR, relative risk reduction.
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Approximately 94% of the CABG cohort experienced an
adverse event, reflecting the severity of the underlying
disease and surgical intervention. Differences between
treatment groups were small. The frequency of adverse
events considered possibly related to treatment was 21.8%
in cariporide patients and 20.0% in placebo patients (Table
6). Small differences between treatment groups were mainly
due to dose-dependent increases in the incidence of confu-
sion and abnormal liver function tests. Confusion tended to
occur early, and no increase was observed at later time
points in the cariporide groups compared with placebo.
Arrhythmias were slightly more common with cariporide
than placebo because of an increase in nonserious adverse
events of atrial fibrillation. However, the incidence of epi-
sodes of atrial fibrillation qualifying as serious adverse
events was similar across treatment groups (Table 6). Other
adverse events showing a trend toward more reports in
cariporide-treated patients included dizziness, dyspnea,
hemorrhage, fever, urinary tract infection, and peripheral
edema. Most were considered mild to moderate in severity.
Changes observed in blood pressure, pulse, ECG parame-
ters, and laboratory evaluations that included hematology,
electrolytes, and metabolism were not considered clinically
relevant.
Predefined serious adverse events that occurred more
frequently with cariporide than placebo included altered
mental status (1.4% in placebo patients vs 2.1% in 120-mg
patients), and renal (2.1% placebo vs 2.3% in 120-mg
patients) and hepatic dysfunction (0.0% placebo vs 0.4% in
120-mg patients). The former event, altered mental status,
presented primarily as confusion, while the latter events
Figure 1. Event-free survival up to 6 months by treatment group. P  .0334.










n (%) n (%) n (%) n (%)
Total subjects with endpoints 120 (16.2) 127 (17.3) 122 (17.3) 89 (12.1)
Total deaths 31 (4.2) 37 (5.0) 30 (4.3) 37 (5.0)
Cardiovascular 28 (3.8) 35 (4.8) 29 (4.1) 33 (4.5)
Sudden death 6 4 0 6
Circulatory failure 18 24 20 22
Other 4 7 9 5
Noncardiovascular 3 (0.4) 2 (0.3) 1 (0.1) 4 (0.5)
MI
Q wave 36 (4.8) 37 (5.0) 39 (5.5) 24 (3.3)
Non-Q wave 53 (7.1) 53 (7.2) 53 (7.5) 28 (3.8)
MI, Myocardial infarction.
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were manifested mainly by abnormal liver and kidney func-
tion tests. Differences between treatment groups were very
small, with no evidence of a clear dose-response relation-
ship. Stroke and transient ischemic attacks occurred in 2.7%
of cariporide 120-mg patients and 2.3% of placebo patients,
but no dose response was observed. In addition, the fre-
quency of these events was comparable between cariporide
and placebo groups in the UA/non–Q-wave MI and PTCA
cohorts. Therefore, the increase observed in the CABG
cohort is likely due to chance. No difference was observed
regarding the occurrence of cardiogenic shock, cardiac isch-
emia, or CHF. Overall, the incidence of serious adverse
events reflected disease severity. No major treatment imbal-
ances were observed. Adverse events led to treatment dis-
continuation in 9.5% of cariporide patients and 6.6% of
placebo patients, mainly for cardiovascular and nervous
system reasons.
Discussion
In the large high-risk CABG cohort of the GUARDIAN
study, a significant 25% RRR in the primary endpoint of
all-cause death or MI at day 36 was observed with caripo-
ride 120 mg administered every 8 hours for an average of 3
days. This observation was also supported by generally










n (%) n (%) n (%) n (%)
Unclassified 25 (3.4) 22 (3.0) 20 (2.8) 28 (3.8)
0 (60 U/L) 562 (75.6) 567 (77.0) 538 (76.3) 582 (79.3)
1 (60-100 U/L) 54 (7.3) 45 (6.1) 52 (7.4) 48 (6.5)
2 (100-200 U/L) 43 (5.8) 47 (6.4) 50 (7.1) 29 (4.0)
3 (200-300 U/L) 19 (2.6) 8 (1.1) 5 (0.7) 8 (1.1)
4 (300 U/L or cardiac death) 40 (5.4) 47 (6.4) 40 (5.7) 39 (5.3)
CK-MB, Creatine kinase with muscle and brain subunits.
TABLE 5. Findings in subgroups of patients
Placebo Cariporide 20 mg Cariporide 80 mg Cariporide 120 mg
Risks factors at study entry
2 Risk factors* (n) 566 580 557 591
Death/MI, d 36 (%) 15.2 14.9 14.0 11.6
3 Risk factors* (n) 197 208 217 214
Death/MI, d 36 (%) 16.8 18.8 15.7 14.1
Repeat CABG* (n) 129 130 124 115
Death/MI, d 36 (%) 27.2 26.9 30.7 18.4
Urgent CABG* (n) 74 57 57 57
Death/MI, d 36 (%) 10.8 15.9 19.3 14.2
Duration of surgery
4.2 h (n) 288 272 278 282
Death/MI, d 36 (%) 8.0 9.2 14.1 7.9
4.2-4.9 h (n) 143 151 141 132
Death/MI, d 36 (%) 15.5 13.2 15.1 9.1
4.9 h (n) 289 293 266 296
Death/MI, d 36 (%) 25.3 26.7 21.5 18.1
Type of cardioplegia
Blood cardioplegia (n) 287 294 284 300
Death/MI, d 36 (%) 18.5 19.1 16.2 14.0
Crystalloid cardioplegia (n) 184 194 172 179
Death/MI, d 36 (%) 14.1 17.5 17.5 9.0
Regional distribution
USA/Canada (n) 514 501 49 506
Death/MI, d 36 (%) 16.1 17.4 17.8 12.8
EUR/rest of world (n) 229 235 236 228
Death/MI, d 36 (%) 16.2 17.0 16.6 11.0
CABG, Coronary artery bypass graft; Eur, Europe; MI, myocardial infarction.
*Patients could be in several categories.
Boyce et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 2 425
CS
P
consistent event rate reductions across subgroups, including
CABG indication, cardioplegia type, and geographic region.
The reduction in risk was observed within 24 hours of
starting treatment and was maintained throughout the
6-month trial. It was primarily driven by a significant (32%)
reduction in the number of nonfatal MIs, both Q-wave and
non-Q-wave, although the mortality rate was similar be-
tween placebo and active treatment. This was associated
with a reduction in infarct size, as shown by reduced peak
CK-MB values. As previously reported, when examining
the CK-MB levels in all 2918 patients enrolled in the CABG
cohort of the GUARDIAN trial, a significant correlation
was found between peak enzyme levels and medium-term
(6 months) prognosis.21 Therefore, the observed MI benefit
in the 120-mg group may translate to an improved mortality
benefit when examining longer-term survival data in a
larger cohort of patients.
The observation of an apparent treatment benefit in the
CABG cohort of the GUARDIAN study, which contrasts
with the overall study findings, may be explained by several
factors. First, patients undergoing CABG had a higher risk
of global myocardial ischemia at baseline than UA/non–Q-
wave MI or PTCA patients and, thus, this cohort was most
likely to demonstrate a benefit. The CABG population also
experienced the longest duration of ischemia. The CABG
cohort had complete myocardial reperfusion while receiving
cariporide, whereas immediate coronary reperfusion was
not specified by the study protocol for the other cohorts.
Finally, the other cohorts experienced an increased number
of events after the end of study treatment, while in the
CABG cohort, the period of risk of myocardial injury was
predominantly during and shortly after surgery. Thus, pro-
nounced differences in the amount of myocardium at risk,
the longer duration of myocardial ischemia, reperfusion in
the presence of cariporide, and the occurrence of endpoint
events after the end of treatment may underlie the apparent
benefit seen in the CABG cohort. This is supported by
preclinical data that demonstrate that activity of NHE-1 is
self-limited during ischemia but is intensified on reperfu-
sion.10,14,18 The reduction in death or MI observed at 36
days was limited to the cariporide 120-mg group. Lower
doses of cariporide were ineffective, suggesting that cari-
poride may have been undertitrated. A subsequent concen-











Most frequent AEs possibly related to treatment (%)
Total subjects with related AEs 20.0 21.5 21.8 21.8
Liver function test abnormal 2.6 3.3 3.3 4.4
Nausea 2.3 2.9 1.9 2.1
Confusion 1.2 2.1 1.4 2.2
Hypotension 1.9 1.8 2.2 1.0
Kidney function abnormal 1.1 1.6 1.4 1.1
Creatinine increased 0.4 1.1 0.7 1.0
GGT increased 0.4 0.4 0.9 1.1
Laboratory test abnormal 0.7 0.7 0.1 1.2
Hypertension 1.0 0.3 0.7 1.1
Vomiting 1.0 0.8 0.3 0.8
Serious AEs of special interest
Altered mental status 1.4 1.4 1.9 2.1
Renal dysfunction 2.1 1.9 1.6 2.3
Liver dysfunction 0.0 0.4 0.4 0.4
Stroke/TIA 2.3 3.3 4.3 2.7
Hemorrhage 4.1 4.3 3.7 3.7
Allergic reaction 0.5 0.1 0.1 0.4
Atrial fibrillation 6.7 5.9 5.5 5.8
Premature discontinuation of study drug
Any discontinuation 10.2 12.2 11.8 15.0
Death 1.3 2.3 1.8 2.2
AEs resulting in drug discontinuation 6.6 8.9 9.5 9.5
Cardiac events 1.9 1.5 1.0 1.6
Kidney disorders 1.4 0.4 1.4 2.5
Hepatic disorders 0.1 0.7 0.0 0.1
CNS events 0.8 1.5 1.4 1.2
AE, Adverse event; CNS, central nervous system; GGT, -glutamyl transpeptidase; TIA, transient ischemic attack.
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netic-modeling techniques identified a minimum mean
cariporide plasma concentration for efficacy of approxi-
mately 550 ng/mL.22 This mean concentration was achieved
in none of the patients in the 20-mg group, in 31% of the
80-mg group, and in 76% of the 120-mg group. Thus, a
modified treatment regimen that increases exposure of pa-
tients to cariporide above this putative threshold concentra-
tion might be associated with increased efficacy. Cariporide,
generally well tolerated compared with placebo, was asso-
ciated with a slight increase in nervous system effects
(mainly transient confusion) and liver and kidney effects,
manifested as isolated elevations in lab tests. No major
treatment imbalances with respect to adverse events were
observed.
Conclusions
The GUARDIAN trial investigated a novel pharmacologic
approach for direct myocardial cell protection. Although no
benefit was observed with any dose of cariporide in the
overall study population, a 25% RRR in all-cause death or
MI was observed with cariporide 120 mg in the CABG
cohort. This statistical positivity is dependent exclusively
on a dramatic reduction in MI. Clinical benefit occurred
early after treatment initiation and continued for 6 months.
The reduction may have been due to the optimal timing of
cariporide administration before global ischemia and during
subsequent reperfusion. The consistent event rate reductions
observed across different CABG subgroups and the heter-
ogeneity of the different GUARDIAN cohorts suggest that
cariporide may be effective in patients undergoing high-risk
CABG surgery. The major limitation of this subanalysis is
that the cariporide 120-mg group of CABG patients repre-
sents only 1 of 3 dosage groups among the 3 cohorts;
therefore the benefit observed may be due to chance. How-
ever, the clinical and pathophysiologic differences between
the entry cohorts and the consistent and persistent risk
reduction seen in the CABG analysis suggest that cariporide
120 mg may be cardioprotective in high-risk patients un-
dergoing CABG. Further investigation of this promising
treatment principle in cardiac surgery is warranted.
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